MASLD & Fatty Liver Disease

MASLD — metabolic dysfunction–associated steatotic liver disease — is the buildup of excess fat in the liver in someone who also has at least one cardiometabolic risk factor, such as prediabetes or type 2 diabetes, overweight or obesity, high blood pressure, elevated triglycerides, or low HDL cholesterol, and who does not drink alcohol in amounts that would by themselves explain the fat. It is the most common chronic liver condition worldwide, affecting more than a third of adults.

In 2023 the major liver societies replaced the older term NAFLD (“nonalcoholic fatty liver disease”) with MASLD, and replaced NASH with MASH (“metabolic dysfunction–associated steatohepatitis”). The new names put the cause — insulin resistance and metabolic dysfunction — front and center, remove the stigma attached to the words “fatty” and “nonalcoholic,” and make the diagnosis a positive one based on identifiable risk factors rather than a diagnosis of exclusion. The conditions describe nearly the same population: in U.S. survey data, about 99% of people who met the old NAFLD definition also meet MASLD criteria.

At-risk MASH means steatohepatitis together with clinically significant fibrosis — stage F2 or higher. This is the group at genuine risk of progressing to cirrhosis, and it is the group screening is designed to find. Among people with type 2 diabetes, roughly 15% to 38% have at-risk MASH.

Very common — and routinely missed. About 70% of people with type 2 diabetes in the U.S. have MASLD, roughly 35% have the more progressive MASH, and about 7% already have MASLD-related cirrhosis. Among people with prediabetes, an estimated 37% to 50% have MASLD. People with prediabetes are about 2.5 times more likely to have MASLD, 8.5 times more likely to have significant fibrosis, and nearly 6 times more likely to have advanced fibrosis than those without.

Because the relationship runs both ways and reaches well beyond the liver. MASLD raises the risk of progressing from prediabetes to type 2 diabetes, and it independently raises the risk of cardiovascular disease — the leading cause of death in people with MASLD. It is also associated with chronic kidney disease and several extrahepatic cancers. Approximately one in five people with type 2 diabetes is on a path toward cirrhosis from MASLD if it goes untreated, making it one of the leading reasons for liver transplant in the United States.

Metabolic health is not only about fat — it is also about muscle. Sarcopenia, the progressive loss of muscle mass and strength, is increasingly recognized as a core part of metabolic and endocrine disease. It commonly accompanies aging, type 2 diabetes, obesity, and fatty liver disease, and when low muscle mass coexists with excess fat — a pattern called sarcopenic obesity — the metabolic risks of each are amplified.

Muscle is a metabolically active organ: it is the body’s largest site for glucose disposal, so losing it worsens insulin resistance and blood sugar control, while also raising the risk of falls, frailty, and loss of independence. Because the same hormonal and metabolic factors we manage — insulin resistance, low testosterone, vitamin D deficiency, thyroid disease, and inactivity — all contribute to muscle loss, sarcopenia is squarely within the scope of endocrine care.

As part of comprehensive metabolic care, we consider muscle health alongside weight and liver assessment, and address it through resistance-oriented exercise guidance, adequate protein and nutrition, correction of underlying hormonal deficiencies, and careful attention to preserving lean mass during weight loss — an especially important consideration for patients using GLP-1–based medications.

We follow the screening pathway endorsed by the American Diabetes Association and the American Association of Clinical Endocrinology. The first step is the FIB-4 index, a simple calculation from your age, AST, ALT, and platelet count — inexpensive, and a reliable way to rule advanced fibrosis out. A FIB-4 under 1.3 means low risk and routine re-checking every one to two years. A FIB-4 above 2.67 indicates high risk and prompts referral to a liver specialist. The large middle group — FIB-4 between 1.3 and 2.67 — needs a second-step test that measures the liver directly.

The second step is a direct measurement of liver stiffness, which reflects the degree of fibrosis. In our office we use the Siemens ACUSON Sequoia ultrasound system with state-of-the-art ARFI (acoustic radiation force impulse) liver-analysis technology, performing this assessment in a single, painless scan. It combines Auto pSWE (point shear-wave elastography), which quantifies liver stiffness with up to 15 valid measurements in seconds, and UDFF (Ultrasound-Derived Fat Fraction), which quantifies liver fat with clinical utility comparable to MRI-PDFF, classifying steatosis at a fat fraction above 5%. In recent biopsy-controlled studies, point shear-wave elastography performs on par with or better than other ultrasound elastography techniques across every fibrosis stage, with validated thresholds for significant fibrosis, advanced fibrosis, and cirrhosis. Measuring both stiffness and fat in one acquisition lets us stratify your risk precisely and follow it over time — without an MRI or a biopsy.

Liver stiffness is reported in kilopascals (kPa) and interpreted against validated thresholds: below roughly 8 kPa indicates a low likelihood of clinically significant fibrosis; the 8–10 kPa range is intermediate; values above roughly 10 kPa suggest advanced fibrosis, and above 15 kPa raise concern for cirrhosis. MASLD is a disease of the metabolic spectrum, and the great majority of patients are best managed right here, where their diabetes, weight, and cardiovascular risk are already being treated. We reserve referral to a hepatologist for the minority with imaging or clinical signs of advanced fibrosis or cirrhosis. We always read the number alongside your FIB-4 score, your cardiometabolic risk factors, and clinical judgment rather than treating any single value as definitive.

Usually not. The whole point of the noninvasive pathway — FIB-4 plus elastography — is to spare most people a biopsy. Biopsy is reserved for cases where the noninvasive tests disagree or are inconclusive, or where another liver disease is suspected, and it is performed by the liver specialist, not here.

Yes. Before attributing fat or elevated liver enzymes to MASLD, we rule out other causes — significant alcohol use, hepatitis B and C, certain medications, and less common conditions — with history and targeted blood work. The CDC recommends at least one-time screening for hepatitis B and C in all adults, and hepatitis C is now curable in nearly everyone.

Weight loss and lifestyle change. The benefits are dose-dependent: losing about 5% of body weight reduces liver fat, roughly 7–10% is usually needed to reverse steatohepatitis, and 10% or more can drive regression of fibrosis. We pair this with a Mediterranean-style eating pattern — rich in vegetables, whole grains, and healthy fats, low in saturated fat, added sugar, and ultra-processed foods — which has the best long-term cardiometabolic and mortality data, plus at least 150 minutes a week of moderate activity and resistance training two to three times weekly.

For people with type 2 diabetes and MASH, the agents with the best evidence do double duty — treating diabetes or obesity while improving the liver. GLP-1 receptor agonists (semaglutide has the strongest evidence, now supported by a phase 3 trial showing improvement in both steatohepatitis and fibrosis) and pioglitazone both improve steatohepatitis; the dual GIP/GLP-1 agonist tirzepatide is promising in phase 2 data. SGLT2 inhibitors, alongside these agents, also reduce cardiovascular risk. In 2024 the FDA approved resmetirom, a thyroid-hormone-receptor-beta agonist, as the first medication specifically for MASH with F2–F3 fibrosis. We individualize the choice to your diabetes, weight, cardiovascular risk, and liver stage.

Metformin, sulfonylureas, DPP-4 inhibitors, and insulin have not been shown to improve steatohepatitis or fibrosis. They remain useful for controlling blood sugar and can be continued for that purpose, but they should not be relied on to treat the liver disease itself. Vitamin E may help selected people without diabetes but is not recommended for those with diabetes or advanced fibrosis on current evidence.

For the right candidate, yes. Metabolic (bariatric) surgery produces durable weight loss and improves steatosis in 70–80% of people, with resolution of inflammation in many and fibrosis improvement in 30–40%, plus major cardiovascular benefit. It is considered with caution in compensated cirrhosis and is not recommended in decompensated cirrhosis. We coordinate this through established surgical programs when appropriate.

It depends on your risk tier. If your FIB-4 is low (under 1.3) we generally repeat it every one to two years. If you have significant fibrosis, we follow you more closely — often with annual elastography on the Sequoia and blood-based fibrosis markers — and we watch for any rise, since an increase of about 30% in liver stiffness signals progression. If you are on treatment, we use the same stiffness measurement to confirm you are responding.

MASLD is best managed by a coordinated team. As your endocrinology practice we lead the metabolic side — diabetes, obesity, cardiovascular risk, and the liver-directed medications — and we bring in dietitians, diabetes educators, and, when fibrosis is advanced, gastroenterology or hepatology. The aim is one integrated plan rather than fragmented care.

If you have diabetes, prediabetes, or obesity, ask us about your liver. A FIB-4 score can be calculated from labs you may already have, and an in-office liver scan takes only minutes. Finding fatty liver early gives us the best possible chance to keep it from ever becoming a problem.